Retirement Systems of Alabama Sells 667 Shares of Illumina, Inc. (NASDAQ:ILMN)

Retirement Systems of Alabama reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 0.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 192,844 shares of the life sciences company’s stock after selling 667 shares during the quarter. Retirement Systems of Alabama owned approximately 0.12% of Illumina worth $25,770,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Versant Capital Management Inc lifted its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the period. TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the period. Private Trust Co. NA boosted its holdings in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares in the last quarter. Focused Wealth Management Inc acquired a new stake in Illumina during the third quarter valued at approximately $63,000. Finally, Hollencrest Capital Management bought a new stake in shares of Illumina in the 3rd quarter valued at approximately $63,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 0.4 %

Shares of ILMN stock opened at $124.68 on Thursday. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The firm has a fifty day moving average of $138.19 and a 200-day moving average of $135.50. The company has a market capitalization of $19.77 billion, a price-to-earnings ratio of -12.52 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Robert W. Baird boosted their price target on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Piper Sandler reduced their target price on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Stephens increased their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and reduced their price target for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada raised their price objective on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $164.84.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.